Return to homepagePandemic Pact

Elaboration of prognostic measures and potential therapies based on severe cases of COVID-19 patients

Grant number: HOSPICOVI2; RITA2/126

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2022

  • Known Financial Commitments (USD)

    $20,190,000.4

  • Funder

    Estonian Research Council

  • Principal Investigator

    Starkopf Joel

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The current project describes COVID-19 hospitalisations in Estonia during 2020, their treatment outcomes and investigates risk factors for severe disease. We will evaluate the treatment standard variety in different hospitals in Estonia. Genetic studies will hopefully provide the risk groups for COVID-19 disease acquisition. We plan to analyze the immune response dynamics of COVID-19 patients during and after hospitalization together with long term evaluation in Estonian cohort of patients. Effectiveness of convalescent plasma therapy in the treatment of COVID-19 patients will be evaluated. There are several different specialities included in the project: clinical medicine, epidemiology and biostatistics, immunology, virology and genetic experts of the University of Tartu. We will cooperate with all the COVID-19 treating hospitals in Estonia. This collaboration will hopefully provide the most important aspects to consider during infectious diseases outbreaks in the future.